FTLP10

Across TCGA pan-cancer cohorts, FTLP10 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of FTLP10’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where FTLP10 RNA is repressed in tumor relative to normal tissue. In most cancer types FTLP10 is over-expressed in tumor, although a few such as HNSC and KIRP show the opposite, repressed pattern.

HNSC, LUSC, and KIRP are the cancer types where FTLP10 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FTLP10 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	III,IV	−1.316	<.001	12	view →
LUSC	All	All	+0.257	<.001	3	view →
KIRP	All	III,IV	−0.135	.040	3	view →
UCEC	All	All	+0.025	.045	2	view →
LIHC	Female	All	−0.008	.032	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

FTLP10–HNSC

Open the HNSC breakdown →